• Users Online: 164
  • Print this page
  • Email this page


 
 Table of Contents  
REVIEW ARTICLE
Year : 2022  |  Volume : 5  |  Issue : 1  |  Page : 1-15

Poststroke aphasia treatment: A review of pharmacologic therapies and noninvasive brain stimulation techniques


1 VA Palo Alto Healthcare System, Polytrauma System of Care, Physical Medicine and Rehabilitation, Palo Alto, CA, USA
2 Baylor College of Medicine, Department of Physical Medicine and Rehabilitation, Houston, TX, USA
3 The University of Texas Health Science Center at Houston, McGovern Medical School, Department of Physical Medicine and Rehabilitation, Houston, Texas, USA

Date of Submission23-Oct-2021
Date of Decision12-Dec-2021
Date of Acceptance13-Dec-2021
Date of Web Publication08-Feb-2022

Correspondence Address:
Dr. Allison Nuovo Capizzi
3801 Miranda Ave. Building MB2, Palo Alto, CA 94304
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jisprm.JISPRM-000151

Rights and Permissions
  Abstract 


Aphasia is a common complication of stroke, often causing significant morbidity. To the authors' knowledge, no stroke recovery practice guidelines incorporating pharmacologic or noninvasive brain stimulation (NIBS) therapies for poststroke aphasia (PSA) exist. The aim of this article is to provide a comprehensive review of the evidence regarding pharmacologic and NIBS treatment in PSA. An exhaustive single database search assessing treatment for PSA was performed from 2010 to 2020, resulting in 1876 articles. Articles evaluating either pharmacologic management or NIBS were included. Case reports, case series, original research, systematic reviews, and meta-analyses were allowed. Pharmacologic treatment studies included were represented by the following medication classes: cholinergic, dopaminergic, gamma-aminobutyric acid agonists and derivatives, N-methyl-D-aspartate receptor antagonists, serotonergic, and autonomic agents. NIBS treatment studies regarding transcranial direct current stimulation (tDCS) or repetitive transcranial magnetic stimulation (rTMS) were evaluated. No strong evidence was found for any medication to improve PSA. However, the benefit of a medication trial may outweigh the risk of side effects as some evidence exists for functional recovery. Regarding NIBS, weak evidence exists for the treatment effect of tDCS and rTMS on PSA. While additional research is needed, the literature shows promise, especially in chronic phase of stroke when traditional treatment options may be exhausted. More evidence with larger studies and standardized study design is needed.

Keywords: Aphasia, stroke rehabilitation, transcranial direct current stimulation, transcranial magnetic stimulation


How to cite this article:
Capizzi AN, Woo JE, Magat E. Poststroke aphasia treatment: A review of pharmacologic therapies and noninvasive brain stimulation techniques. J Int Soc Phys Rehabil Med 2022;5:1-15

How to cite this URL:
Capizzi AN, Woo JE, Magat E. Poststroke aphasia treatment: A review of pharmacologic therapies and noninvasive brain stimulation techniques. J Int Soc Phys Rehabil Med [serial online] 2022 [cited 2022 May 23];5:1-15. Available from: https://www.jisprm.org/text.asp?2022/5/1/1/337424




  Introduction Top


At 1 year following a stroke, approximately 40% of patients are still living with aphasia, a significant cause of morbidity.[1] Lesions to the language centers of the brain, predominantly in the left hemisphere, may result in aphasia. The literature suggests that perilesional regions as well as ipsilateral and contralateral areas contribute to necessary reorganization process required for aphasia recovery.[1] Three general models of aphasia recovery exist. Vicariation is the concept that the hemisphere contralateral to the lesion entirely replaces the lost function of the damaged hemisphere. The interhemispheric competition model assumes that, at baseline (preinjury), the two cerebral hemispheres inhibit each other. Once an injury occurs, the hemisphere contralateral to the lesioned hemisphere inhibits the lesioned hemisphere to a greater degree, limiting recovery of the functions within the lesioned hemisphere. The bimodal balance recovery theory suggests that the amount of undamaged neurons, a type of structural reserve, connecting injured to uninjured areas of the brain, determines the recovery potential.[2] The aim of this article is to provide a thorough review of the literature addressing pharmacologic and noninvasive brain stimulation (NIBS) interventions as treatment options for poststroke aphasia (PSA).


  Methods Top


This article is a narrative review of the existing literature, and therefore, no human subjects were involved. No informed consent was necessary. As a review, this study was exempt from institutional review board approval. Two exhaustive single database (PubMed) searches were performed with assistance from a skilled librarian evaluating treatments for PSA over a 10-year period (2010–2020). The first search produced 781 results primarily yielding articles on NIBS. The second search was expanded to include all therapy modalities and pharmacologic treatment (1088 results). Complete search terms are included in Supplementary Material. These were screened for relevance by the three authors. Articles on NIBS including transcutaneous direct current stimulation (tDCS) and repetitive transcranial magnetic stimulation (rTMS) as well as pharmacologic treatments were included. Articles solely focusing on other modalities (such as isolated speech therapy) were excluded. Case reports, case series, original research, systematic reviews, and meta-analyses were included if appropriate for the purpose of the article.


  Pharmacologic Trials for Poststroke Aphasia Top


Cholinergic medications

Ischemic changes in the brain can interrupt the cholinergic projections to cortical areas necessary for language processing.[3],[4],[5] Language deficits are common in Alzheimer's dementia (AD) wherein single-photon emission computed tomography and positron emission tomography show cortical acetylcholine (ACh) reduction.[6],[7],[8] Early neurochemical studies also suggested a loss of cholinergic neurons or decrease in choline acetyltransferase activity.[6],[8] An ACh receptor antagonist, scopolamine, resulted in cognitive impairment and dose-dependent decline in reading, spelling, verbal fluency, and object naming in healthy subjects.[9],[10] On the other hand, an acetylcholinesterase (AChE) inhibitor, physostigmine, improved naming in three patients with anomia.[11] These findings are cited as a rationale for cholinergic medication trials in PSA.

Bifemelane

In animal studies, bifemelane prevented N-methyl-D-aspartate (NMDA) and muscarinic cholinergic receptors' reduction in ischemia and increased ACh release.[12],[13],[14] Two small clinical trials were found in the literature [Table 1]. Both point to the benefits of this medication in improving language impairments.
Table 1: Cholinergic medications

Click here to view


Galantamine

Galantamine is a reversible and competitive AChE inhibitor.[15],[21] This review yielded one study [Table 1] which showed significant improvement in the experimental group's global aphasia severity score.[15]

Donepezil

Donepezil increases ACh via reversible inhibition of AChE.[22] Interest in donepezil for PSA stemmed from earlier studies demonstrating improvements in AD patients' language deficits while taking this medication.[16] The literature yields many published articles showing language improvement in PSA [Table 1].[16],[17],[18],[19],[20]

Dopaminergic medications

Observations of speech improvement following Levodopa (L-dopa) therapy in parkinsonian patients encouraged studies evaluating dopaminergic agents for PSA.[23] Some researchers suggest decreased dopamine input to the frontal lobe causes aphasia in the left frontal lesions by inhibiting the mesocortical pathway.[24],[25],[26] Two dopaminergic medications, bromocriptine and L-dopa, are studied for aphasia.[23]

Bromocriptine

Bromocriptine is a postsynaptic dopamine receptor agonist.[27] The seven bromocriptine trials on PSA primarily involve nonfluent aphasia subjects [Table 2]. The results are variable. Most benefits were noted in smaller studies, case reports, and open-label trials with no placebo. Most double-blinded placebo-controlled trials did not show any significant benefits with bromocriptine compared to placebo.[28],[29],[30],[32] The presence of significant side effects, if mentioned in the articles, appears related to higher medication doses.[31]
Table 2: Dopaminergic medications

Click here to view


Levodopa

A 2004 study involving nonaphasic subjects demonstrated accelerated word learning while taking L-dopa.[33] This study, along with the bromocriptine studies, prompted trials evaluating L-dopa for PSA. Three trials [Table 2] were identified in our literature search, with 2 out of 3 showing no significant effects for PSA.[33],[34],[35]

GABAergic medications

Zolpidem

Zolpidem is an imidazopyridine, a gamma-aminobutyric acid A (GABA A) receptor agonist. This medication is unique, being a selective agonist of the alpha 1 subunit of the GABA A receptor complex.[36],[37],[38] Reports of its use outside of insomnia started in the late 1990s.[39] Most studies evaluating alternate applications of zolpidem focus on indications for movement disorders and disorders of consciousness (DOC). In the DOC population, zolpidem is theorized to bind GABA A receptors on the dormant nerve cells, leading to normalizing metabolic activity, and restore the pathway connectivity to improve alertness.[38]

Two articles evaluated zolpidem in PSA treatment [Table 3]. One study showed speech improvement, while the other showed naming task improvement. One study theorized that select patients with subcortical lesions and hypometabolic cortical structures may benefit from zolpidem.[37]
Table 3: Zolpidem

Click here to view


Piracetam

Piracetam is a GABA derivative and is the first nootropic agent theorized to have neuroprotective properties by increasing gray matter cerebral blood flow.[40],[41] In healthy subjects, piracetam may improve learning and memory.[42] Piracetam's mechanism of action is unknown but may include facilitating ACh and excitatory amino acid release.[41],[42],[43] Initial clinical trials suggested aphasia improvement with piracetam versus placebo group.[44] These include studies by Herrschaft in 1988 and Platt et al. in 1992.[44] Most subsequent studies were blinded randomized control trials (RCTs) [Table 4].[45],[46] Study outcomes showed improvements in different aspects of language and speech except for one, which did not show clear benefit.[47] A systematic review by Zhang et al. was published in 2016, aiming to assess piracetam in PSA rehabilitation.[48] Seven RCTs were reviewed [Table 4]. This meta-analysis demonstrated short-lived positive effects in written language improvement, but overall aphasia severity did not improve.[48]
Table 4: Piracetam

Click here to view


N-methyl-D-aspartate receptor antagonist

Memantine

Glutamate is a major mediator of neuronal plasticity and cell injury/death.[49],[50] The glutamatergic system requires a finely balanced control, with both hypoactivity and hyperactivity of the glutamatergic system, leading to dysfunction.[50] A 1998 animal study showed imbalances between excitatory and inhibitory binding sites in areas away from ischemic tissue damage, namely an upregulation in NMDA receptors binding sites and downregulation of GABA A receptors.[51] Memantine is an uncompetitive (channel-blocking) antagonist of the NMDA-receptor subtype of glutamate receptors.[49],[50],[54] Memantine may have the potential to interrupt glutamatergic-mediated neurotoxic cascades without interfering with normal glutamatergic signals.[50],[55]

A summary of seven studies evaluating the effect of memantine on language or communication in AD and other diagnoses was published in 2014. This 2014 publication showed modest language and communication benefits in AD patients taking memantine, prompting additional research evaluating memantine for PSA severity. One study demonstrated improvement. [Table 5].[56]
Table 5: Memantine

Click here to view


Serotonergic medications

Many clinical and preclinical trials suggest that antidepressants, including selective serotonin reuptake inhibitors (SSRIs), provide benefits to stroke outcomes independent of antidepression effect.[58],[59] Previously cited possible indications for SSRIs in poststroke recovery include neuroprotection by reduction of inflammation, enhancement of neurogenesis, modulation of cortical excitability, reestablishment of inhibitory neural network tone, cerebral blood flow regulation, modulation of the autonomic nervous system, and genetic and epigenetic correlates.[58],[60] A meta-analysis of animal studies by McCann et al. in 2014[61] showed that antidepressants may improve infarct volume and neurobehavioral outcome. In clinical trials, several experiments and meta-analyses suggest improved stroke recovery with SSRI use.[62],[63],[64] However, more recent meta-analyses concluded that SSRIs do not improve disability or independence,[65] and if filtered for low bias, no studies evaluating SSRIs in stroke recovery show significant improvement.[66]

Three trials investigating SSRI and its effects on PSA were found in the literature, as summarized in [Table 6].[67],[68],[69] Two trials showed improvement in the Boston naming test.[67],[68]
Table 6: Selective serotonin reuptake inhibitors

Click here to view


Autonomic medications

Dextroamphetamine

Dextroamphetamine is a noncatecholamine, sympathomimetic amine.[70] Animal experiments in the 1980s into the 2000s furnished evidence pointing to the role of brain catecholamine in the recovery of function.[71],[72] One of the most studied agents was amphetamine.[71] The mechanism of recovery appears to lie in improved neurite growth and formation of synapses.[73],[74],[75],[76] A preclinical trial and several clinical trials showed improvement in motor function with amphetamine after a stroke.[72] One study showed that a catecholamine antagonist hindered recovery from aphasia.[77] These led to trials aiming to determine the effect of dextroamphetamine on PSA. Older trials were case studies and case series, with majority of studies thereafter using double-blinded, placebo-controlled designs. These trials, summarized in [Table 7],[71],[73],[74],[75],[78],[79],[80],[81] resulted toward positive improvements in aphasia, except for one;[78] however, only one subject was enrolled in this study arm.
Table 7: Medications affecting the sympathetic system

Click here to view


Atomoxetine

Atomoxetine is a selective norepinephrine reuptake inhibitor at the presynaptic level.[83],[84] One study was found in the literature suggesting a positive outcome with use in aphasia patients [Table 7].[80]

Propranolol

Propranolol is a nonselective beta-adrenergic receptor blocking agent.[85] Several early studies showed improvement with propranolol use in cognitive flexibility during stressful situations and improvement in problem-solving tasks involving lexical-semantic networks.[81] A 1986 three-arm retrospective study included aphasic male subjects taking either propranolol, hydrochlorothiazide (HCTZ), or no treatment. Results indicated that participants taking propranolol had a better recovery than those on HCTZ.[82] A 2007 double-blind cross-over design pilot study investigating the effect of propranolol on PSA[81] showed benefit in naming [Table 7].


  Noninvasive Brain Stimulation for Poststroke Aphasia Top


Transcutaneous direct current stimulation

Aphasia recovery is considered driven, in part, by spontaneous neuroplasticity. NIBSs such as rTMS and tDCS have been tried as complementary instruments to speech and language therapy (SLT) to promote poststroke reorganization of language networks for optimal recovery.[1] tDCS modulates cortical excitability by changing the resting membrane potential via application of small currents (1–2 mA) to the scalp through the electrodes over a time period (5–30 min) where the anode increases excitability of the underlying cortex, and the cathode decreases it.[86] Based on the schematic model of interhemispheric competition as previously mentioned, most tDCS studies have used anodal stimulation on the left hemisphere such as Broca's (left inferior frontal gyrus) area for activation or cathodal stimulation on the right hemisphere such as Broca's homolog for inhibition.[1],[87],[88] Once a stimulation target is determined, several techniques such as fMRI, rTMS, and, most commonly, electroencephalography electrode positioning system can be used to precisely locate the lesion and to place electrodes for each patient.[89] Unlike rTMS, tDCS can be used online, meaning patients can participate in language tasks during stimulation, which was found more effective than offline treatment.[89]

Numerous reviews and meta-analyses have been published with conflicting findings regarding the efficacy of tDCS for improving PSA. Otal et al. did not show significant treatment effects in a 2015 meta-analysis.[90] Shah-Basak et al.'s meta-analysis highlighted significant improvement in language outcome in chronic stages.[91] Meta-analyses by Elsner et al. in 2013, 2015, and 2019 found no effectiveness of tDCS versus control for improving functional communication, naming verbs, and cognition. However, the 2019 study did note improved noun-naming accuracy compared to control group.[92] Another meta-analysis by Rosso et al. demonstrated a significant dose-dependent effect of repetitive tDCS on naming accuracy in chronic stroke patients, more for anodal than cathodal tDCS and for left than right hemisphere stimulation.[93] The most recent meta-analysis in 2019 concluded that tDCS may improve aphasia recovery and produce durable results, especially for the naming performance, in the chronic phase.[1]

A 2019 systematic review by Biou et al. highlighted the effects of anodal tDCS over Broca's area combined with various language training tasks. Simultaneous repetition tasks improved accuracy in speech production, naming tasks improved naming accuracy, and conversational therapy improved picture naming, noun, and verb naming.[89] Participants also demonstrated more informative and cohesive speech,[33],[36] as well as improved reading ability.[94] The authors concluded that selecting the correct combination between the behavioral task and stimulation site was crucial to optimize the combined effects of tDCS and language training.[89] For other specific areas, cathodal stimulation over the right Wernicke's homolog, anodal stimulation over the Wernicke's area, and anodal stimulation over the left posterior perisylvian region improved auditory verbal comprehension.[95],[96] The authors concluded that tDCS was effective for PSA rehabilitation in the chronic stages.

Interestingly, improvement has been found after both anodal and/or cathodal stimulation over the right hemisphere in studies which seems counterintuitive in models of interhemispheric competition.[89] However, as per vicariation model, the right hemisphere may aid aphasia recovery.[97] Inhibiting the right hemisphere might be useful only when its activity is excessive and maladaptive but might be harmful when the right hemisphere activity is compensatory.[89] In a review article, Bucur and Papagno noted that stroke phase determines the brain state, and ongoing plastic changes may influence treatment effect. The authors presented the potential efficacy of downregulating the right hemisphere during the subacute period and activating the perilesional regions during the chronic phase.[1] Similar to this, Biou et al. concluded that right Broca's homolog and supplementary motor area seem involved in the subacute phase of stroke, followed by a normalization and re-shifting of cortex activity toward the left during the chronic stage.[89] Hence, many trials that aimed to facilitate the left hemisphere during the subacute phase did not find significant results.[89] The conclusion suggesting a shift in language area activation in acute versus chronic stroke is further supported by Saur et al.'s fMRI observations on dynamics of language reorganization. Saur et al. showed reduced activation of perilesional language areas in the acute phase of stroke, followed by an upregulation with recruitment of the right Broca's homolog, which strongly correlated with improved language function. This shift was followed by normalization of activation patterns during the chronic phase which was associated with further language improvement.[98]

Several uncommon stimulation sites have been targeted with the principle of improving language via modulation of motor-language connections. Anodal stimulation of the left dorsolateral prefrontal cortex and primary motor cortex has shown to improve verbal fluency[99] and functional communication,[100] respectively, both of which propose a need for motor networks in aphasia recovery.[89] Other studies found improved spelling,[101] verb generation,[102] and verbal fluency,[103] with various cerebellar stimulations. Cerebellar stimulation is thought to improve the nonlinguistic aspects of task performance through its contribution in higher-level cerebral functions.[102],[104] One study stimulated the spinal cord with positive effects on verb retrieval, suggesting its influence on the ascending somatosensory pathways, ultimately modulating the language network in the sensorimotor cortex.[86]

No study reported serious adverse effects of tDCS. Side effects reported include local discomfort at the stimulation site, such as itching and tingling, dull headache, and dizziness.[1]

There were several prominent limitations that could cause inconsistent findings among tDCS trials. Study designs are significantly heterogeneous varying in the number of sessions, treatment frequency, intervention protocol, tDCS montage, types and chronicity of stroke, aphasic symptoms and severity, patient's anatomy, etc. There is also a concern for genetic variation affecting the response to tDCS. Fridriksson et al. found that patients with a typical BDNF genotype seemed to have milder symptoms of aphasia and better improvement induced by anodal tDCS.[105] Another major limitation is the lack of comprehensive aphasia assessment tools. Picture naming task was selected as a central measure of language improvement in many studies although some investigated fluency, reading, and auditory-verbal comprehension.[1] However, functional communication cannot be fully represented by the outcomes measured in single-word production.[106] There is only a few studies that explored the effects of tDCS on suprasegmental and other subtle aspects of language such as intonation, pitching, and prosody.[93] Most of the available objective measures are not able to detect the ease of task and performance that patients experience.

Repetitive transcranial magnetic stimulation

rTMS is a NIBS technique that uses pulses of electromagnetic waves at certain frequencies to enhance recovery of brain functions.[2],[107] The studied applications for rTMS are numerous, including pain, movement disorders, epilepsy, DOC, tinnitus, depression, anxiety disorders, obsessive–compulsive disorder, schizophrenia, craving/addiction, and conversion, among others.[107]

Similar to the proposed mechanisms discussed regarding tDCS, rTMS for aphasia recovery utilizes principles from the interhemispheric competition model for recovery.[2] As in tDCS, meta-analyses of rTMS suggest that the best outcomes of rTMS therapy occur when electromagnetic current is directed to the area contralateral to the initial lesion. For example, if the injury resulted in a nonfluent aphasia, then rTMS treatment would be targeted at the right inferior frontal gyrus near Brodmann's area 44 or 45, contralateral to Broca's area in the left hemisphere. The magnetic current modulates cortical excitability, therefore dampening excess inhibition from the contralateral cortex on the lesioned cortex. By suppressing the inhibiting signals from the contralateral area, the lesioned area then gains more potential for recovery.[2],[107]

Lefaucheur et al. published comprehensive evidence-based guidelines regarding rTMS therapy in 2014 followed by an update in 2020. These guidelines discuss the evidence of rTMS for multiple conditions, including PSA. Research before 2012 evaluating rTMS for PSA recovery displayed mixed findings. Similar to the limitations noted in the tDCS review section, ambiguity in effectiveness of rTMS may be attributed to the heterogeneity in study designs which previously included all types of aphasia and poststroke patients at all phases of recovery.[107]

Literature after 2012, with more specific inclusion criteria, reveals that the placement of the magnet and the type of rTMS appear to have a significant role in the effectiveness of the intervention. There is evidence low-frequency rTMS (LF-rTMS) is associated with aphasia recovery while high-frequency rTMS does not seem to offer a significant impact. While dual hemisphere stimulation may be beneficial,[108],[109] stimulation ipsilateral to the lesion has not proven helpful.[107] To date in this current review, only contralateral rTMS is associated with significant benefit in PSA recovery.[107],[109]

Additional factors including time since injury and type of aphasia appear linked with the amount of benefit derived from rTMS treatment. Thus far, chronic stroke patients (where chronic is defined as greater than 6 months poststroke) are the only population who consistently experienced statistically significant language improvements from rTMS treatments. Within the chronic poststroke population, there is class B level of evidence suggesting that patients with nonfluent aphasia may benefit from rTMS therapy.[107]

While research protocols vary, those which reported positive findings generally used LF-rTMS with a frequency of 1 HZ and an intensity of 90%. The number of pulses varied from 600 to 1200 and the number of total sessions varied from 10 to 20 per study.[107],[109],[100],[110],[111]

There are several limitations to evaluation of rTMS therapy. Study design heterogeneity is a significant concern facing similar challenges to those described within the tDCS section. It is difficult to interpret the lasting effects of rTMS because most long-term follow-up studies did not track outcomes beyond 3 months, likely restricted by resources and funding.[110] In addition, while rTMS may have statistically significant therapeutic benefit in a research study, the findings may not translate into clinical significance. In addition, to our knowledge, no study with significant findings supporting rTMS used NIBS to treat aphasia in isolation, all compared rTMS with SLT against SLT alone.

Negative side effects related to rTMS are rare. One study by Bae et al., evaluating rTMS in epilepsy patients, noted that 83% of participants experienced no side effects. Of the 17% of participants that experienced side effects, transient headache was the most common followed by a general feeling of discomfort or weakness. Very rarely, seizures have been reported (1.4%), though seizures were associated with patients already diagnosed with epilepsy.[112]


  Discussion Top


Pharmacologic interventions for PSA aim to augment neurotransmitter activity and the neurochemical networks that are believed to be compromised after a stroke. Although no strong evidence exists for any particular medication to improve PSA, the benefit of a medication trial may outweigh the risk of side effects. In addition, pharmacotherapy can play a role in other neurocognitive pathways and enhance overall function during recovery. Current published reviews and meta-analyses provide weak evidence for treatment effect of tDCS and rTMS on PSA due to a small number of original experimental studies, the heterogeneity of the procedures, a paucity of comprehensive assessment tools for language, and vague understanding of brain reorganization mechanisms. However, the authors of the recent studies are optimistic about the therapeutic effects of NIBS, especially in chronic phase of stroke when no other treatment options are typically available.

Most articles assessing PSA treatment evaluated SLT with either pharmacotherapy or NIBS and did not combine these modalities together. One 2017 study by Keser et al. evaluated the combined effect of pharmacotherapy with NIBS to examine the effect of triple therapy.[75] This was a small cross-over, placebo-controlled, double-blinded trial of chronic poststroke patients with nonfluent aphasia. The participants received a baseline language assessment followed by either 10 mg of dextroamphetamine or a placebo before undergoing tDCS with simultaneous SLT (triple-combination therapy). The Western Aphasia Battery-Revised and Language Quotient were administered before and after the combination treatments. They underwent two cycles of treatment, one experimental and one placebo, with a washout period of approximately 1 week in between. The results show a statistically significant increase in the Aphasia Quotient and Language Quotient in the experimental group compared to placebo. However, the small sample size, short study duration, and low number of treatment sessions limit the broader application of these findings. Despite limitations, Keser et al. highlight the safety and feasibility of their proof-of-concept design for future research.


  Conclusion Top


The current review finds a lack of strong evidence supporting specific pharmacotherapy and NIBS protocols in management of PSA. However, these treatments may be appropriate to trial on a case-by-case basis under a specialist's guidance, especially in the chronic poststroke phase when standard-of-care therapies have had limited results. Further research is needed, particularly with triple therapy, as noted in Keser et al. Regarding NIBS, finding positive effects of tDCS and rTMS on social communication, overall functional outcome, mood, quality of life, and participation would enhance its clinical values. At last, NIBS safety,[113] relatively low cost, ease of application, and great potential to improve PSA warrant further research.[1],[92]

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Bucur M, Papagno C. Are transcranial brain stimulation effects long-lasting in post-stroke aphasia? A comparative systematic review and meta-analysis on naming performance. Neurosci Biobehav Rev 2019;102:264-89.  Back to cited text no. 1
    
2.
Fisicaro F, Lanza G, Grasso AA, Pennisi G, Bella R, Paulus W, et al. Repetitive transcranial magnetic stimulation in stroke rehabilitation: Review of the current evidence and pitfalls. Ther Adv Neurol Disord 2019;12:1-22. DOI 10.1177/175628419878317.  Back to cited text no. 2
    
3.
Berthier ML, Green C, Higueras C, Fernández I, Hinojosa J, Martín MC. A randomized, placebo-controlled study of donepezil in poststroke aphasia. Neurology 2006;67:1687-9.  Back to cited text no. 3
    
4.
Mesulam M, Siddique T, Cohen B. Cholinergic denervation in a pure multi-infarct state: Observations on CADASIL. Neurology 2003;60:1183-5.  Back to cited text no. 4
    
5.
Román GC, Kalaria RN. Vascular determinants of cholinergic deficits in Alzheimer disease and vascular dementia. Neurobiol Aging 2006;27:1769-85.  Back to cited text no. 5
    
6.
Tanaka Y, Miyazaki M, Albert ML. Effects of increased cholinergic activity on naming in aphasia. Lancet 1997;350:116-7.  Back to cited text no. 6
    
7.
Roy R, Niccolini F, Pagano G, Politis M. Cholinergic imaging in dementia spectrum disorders. Eur J Nucl Med Mol Imaging 2016;43:1376-86.  Back to cited text no. 7
    
8.
Lendon CL, Ashall F, Goate AM. Exploring the etiology of Alzheimer disease using molecular genetics. JAMA 1997;277:825-31.  Back to cited text no. 8
    
9.
Drachman DA, Leavitt J. Human memory and the cholinergic system. A relationship to aging? Arch Neurol 1974;30:113-21.  Back to cited text no. 9
    
10.
Aarsland D, Larsen JP, Reinvang I, Aasland AM. Effects of cholinergic blockade on language in healthy young women. Implications for the cholinergic hypothesis in dementia of the Alzheimer type. Brain 1994;117:1377-84.  Back to cited text no. 10
    
11.
Jacobs D, Shuren J, Gold M, Adair J, Bowers D, Williamson D, et al. Physostigmine pharmacotherapy for anomia. Neurocase 1996;2:83-91.  Back to cited text no. 11
    
12.
Hata R, Matsumoto M, Kitagawa K, Tagaya M, Matsuyama T, Sugita M, et al. Therapeutic effect of bifemelane on unilateral cerebral ischemia in gerbils. Life Sci 1995;57:379-86.  Back to cited text no. 12
    
13.
Minami M, Arai H, Takahashi T, Kimura M, Noguchi I, Suzuki T, et al. A preliminary study on plasma concentrations of bifemelane, indeloxazine and propentofylline in aged patients with organic brain disorders. Prog Neuropsychopharmacol Biol Psychiatry 1995;19:59-64.  Back to cited text no. 13
    
14.
Kabasawa H, Matsubara M, Kamimoto K, Hibino H, Banno T, Nagai H. Effects of bifemelane hydrochloride on cerebral circulation and metabolism in patients with aphasia. Clin Ther 1994;16:471-82.  Back to cited text no. 14
    
15.
Hong JM, Shin DH, Lim TS, Lee JS, Huh K. Galantamine administration in chronic post-stroke aphasia. J Neurol Neurosurg Psychiatry 2012;83:675-80.  Back to cited text no. 15
    
16.
Tsz-Ming C, Kaufer DJ. Effects of donepezil on aphasia, agnosia and apraxia in patients with cerebrovascular lesions. J Neuropsychiatry Clin Neurosci 2001;13:140.  Back to cited text no. 16
    
17.
Berthier ML, Hinojosa J, Martín Mdel C, Fernández I. Open-label study of donepezil in chronic poststroke aphasia. Neurology 2003;60:1218-9.  Back to cited text no. 17
    
18.
Yoon SY, Kim JK, An YS, Kim YW. Effect of donepezil on wernicke aphasia after bilateral middle cerebral artery infarction: Subtraction analysis of brain F-18 fluorodeoxyglucose positron emission tomographic images. Clin Neuropharmacol 2015;38:147-50.  Back to cited text no. 18
    
19.
Berthier ML, De-Torres I, Paredes-Pacheco J, Roé-Vellvé N, Thurnhofer-Hemsi K, Torres-Prioris MJ, et al. Cholinergic potentiation and audiovisual repetition-imitation therapy improve speech production and communication deficits in a person with crossed aphasia by inducing structural plasticity in white matter tracts. Front Hum Neurosci 2017;11:304.  Back to cited text no. 19
    
20.
Berthier ML, Dávila G, Green-Heredia C, Moreno Torres I, Juárez y Ruiz de Mier R, De-Torres I, et al. Massed sentence repetition training can augment and speed up recovery of speech production deficits in patients with chronic conduction aphasia receiving donepezil treatment. Aphasiology 2014;28:188-218.  Back to cited text no. 20
    
21.
Trademark (Galantamine HBR) Extended-Release Capsules. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021615lbl.pdf. [Last accessed on 2020 Oct 19].  Back to cited text no. 21
    
22.
Aricept (Donepezil Hydrochloride) Label. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020690s035,021720s008,022568s005lbl.pdf. [Last accessed on 2020 Oct 19].  Back to cited text no. 22
    
23.
Gill SK, Leff AP. Dopaminergic therapy in aphasia. Aphasiology 2012;28:155-70.  Back to cited text no. 23
    
24.
Sabe L, Salvarezza F, García Cuerva A, Leiguarda R, Starkstein S. A randomized, double-blind, placebo-controlled study of bromocriptine in nonfluent aphasia. Neurology 1995;45:2272-4.  Back to cited text no. 24
    
25.
Raymer AM, Bandy D, Adair JC, Schwartz RL, Williamson DJ, Gonzalez Rothi LJ, et al. Effects of bromocriptine in a patient with crossed nonfluent aphasia: A case report. Arch Phys Med Rehabil 2001;82:139-44.  Back to cited text no. 25
    
26.
Seniów J, Litwin M, Litwin T, Leśniak M, Członkowska A. New approach to the rehabilitation of post-stroke focal cognitive syndrome: Effect of levodopa combined with speech and language therapy on functional recovery from aphasia. J Neurol Sci 2009;283:214-8.  Back to cited text no. 26
    
27.
Parlodel. Available form: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/017962s065s068lbl.pdf. [Last accessed on 2020 Oct 19].  Back to cited text no. 27
    
28.
Gupta SR, Mlcoch AG. Bromocriptine treatment of nonfluent aphasia. Arch Phys Med Rehabil 1992;73:373-6.  Back to cited text no. 28
    
29.
Ozeren A, Sarica Y, Mavi H, Demirkiran M. Bromocriptine is ineffective in the treatment of chronic nonfluent aphasia. Acta Neurol Belg 1995;95:235-8.  Back to cited text no. 29
    
30.
Gold M, VanDam D, Silliman ER. An open-label trial of bromocriptine in nonfluent aphasia: A qualitative analysis of word storage and retrieval. Brain Lang 2000;74:141-56.  Back to cited text no. 30
    
31.
Bragoni M, Altieri M, Di Piero V, Padovani A, Mostardini C, Lenzi GL. Bromocriptine and speech therapy in non-fluent chronic aphasia after stroke. Neurol Sci 2000;21:19-22.  Back to cited text no. 31
    
32.
Ashtary F, Janghorbani M, Chitsaz A, Reisi M, Bahrami A. A randomized, double-blind trial of bromocriptine efficacy in nonfluent aphasia after stroke. Neurology 2006;66:914-6.  Back to cited text no. 32
    
33.
Knecht S, Breitenstein C, Bushuven S, Wailke S, Kamping S, Flöel A, et al. Levodopa: Faster and better word learning in normal humans. Ann Neurol 2004;56:20-6.  Back to cited text no. 33
    
34.
Leemann B, Laganaro M, Chetelat-Mabillard D, Schnider A. Crossover trial of subacute computerized aphasia therapy for anomia with the addition of either levodopa or placebo. Neurorehabil Neural Repair 2011;25:43-7.  Back to cited text no. 34
    
35.
Breitenstein C, Korsukewitz C, Baumgärtner A, Flöel A, Zwitserlood P, Dobel C, et al. L-dopa does not add to the success of high-intensity language training in aphasia. Restor Neurol Neurosci 2015;33:115-20.  Back to cited text no. 35
    
36.
Hall SD, Yamawaki N, Fisher AE, Clauss RP, Woodhall GL, Stanford IM. GABA(A) alpha-1 subunit mediated desynchronization of elevated low frequency oscillations alleviates specific dysfunction in stroke – A case report. Clin Neurophysiol 2010;121:549-55.  Back to cited text no. 36
    
37.
Cohen L, Chaaban B, Habert MO. Transient improvement of aphasia with zolpidem. N Engl J Med 2004;350:949-50.  Back to cited text no. 37
    
38.
Bomalaski MN, Claflin ES, Townsend W, Peterson MD. Zolpidem for the treatment of neurologic disorders: A systematic review. JAMA Neurol 2017;74:1130-9.  Back to cited text no. 38
    
39.
NDA 19908 S027 FDA Approved Labeling 4.23.08. Available form: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/01990 8s027lbl.pdf. [Last accessed on 2020 Oct 19].  Back to cited text no. 39
    
40.
De Deyn PP, Reuck JD, Deberdt W, Vlietinck R, Orgogozo JM. Treatment of acute ischemic stroke with piracetam. Members of the Piracetam in Acute Stroke Study (PASS) Group. Stroke 1997;28:2347-52.  Back to cited text no. 40
    
41.
Kessler J, Thiel A, Karbe H, Heiss WD. Piracetam improves activated blood flow and facilitates rehabilitation of poststroke aphasic patients. Stroke 2000;31:2112-6.  Back to cited text no. 41
    
42.
Aronson JK. Meyler's Side Effects of Drugs. The International Encyclopedia of Adverse Drug Reactions and Interactions. 16th ed. New York, NY: Elsevier Science; 2016. p. 785-6. Available form: https://reader.elsevier.com/reader/sd/pii/B9780444537171012907?token=828D243E5CCD67EB2EDE879 5DCED57814055EAE47E95574DAE651F6377CA E69AB57186CA833813C3625B0F1235E1F344. [Last accessed on 2020 Oct 19].  Back to cited text no. 42
    
43.
Enderby P, Broeckx J, Hospers W, Schildermans F, Deberdt W. Effect of piracetam on recovery and rehabilitation after stroke: A double-blind, placebo-controlled study. Clin Neuropharmacol 1994;17:320-31.  Back to cited text no. 43
    
44.
Huber W. The role of piracetam in the treatment of acute and chronic aphasia. Pharmacopsychiatry 1999;32 Suppl 1:38-43.  Back to cited text no. 44
    
45.
Orgogozo JM. Piracetam in the treatment of acute stroke. Pharmacopsychiatry 1999;32 Suppl 1:25-32.  Back to cited text no. 45
    
46.
Szelies B, Mielke R, Kessler J, Heiss WD. Restitution of alpha-topography by piracetam in post-stroke aphasia. Int J Clin Pharmacol Ther 2001;39:152-7.  Back to cited text no. 46
    
47.
Güngör L, Terzi M, Onar MK. Does long term use of piracetam improve speech disturbances due to ischemic cerebrovascular diseases? Brain Lang 2011;117:23-7.  Back to cited text no. 47
    
48.
Zhang J, Wei R, Chen Z, Luo B. Piracetam for aphasia in post-stroke patients: A systematic review and meta-analysis of randomized controlled trials. CNS Drugs 2016;30:575-87.  Back to cited text no. 48
    
49.
Zhou Y, Danbolt NC. Glutamate as a neurotransmitter in the healthy brain. J Neural Transm (Vienna) 2014;121:799-817.  Back to cited text no. 49
    
50.
Parsons CG, Stöffler A, Danysz W. Memantine: A NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system – Too little activation is bad, too much is even worse. Neuropharmacology 2007;53:699-723.  Back to cited text no. 50
    
51.
Qü M, Mittmann T, Luhmann HJ, Schleicher A, Zilles K. Long-term changes of ionotropic glutamate and GABA receptors after unilateral permanent focal cerebral ischemia in the mouse brain. Neuroscience 1998;85:29-43.  Back to cited text no. 51
    
52.
Namenda. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021487s010s012s014,021627s008lbl.pdf. [Last accessed on 2020 Sep 23].  Back to cited text no. 52
    
53.
Rogawski MA, Wenk GL. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Rev 2003;9:275-308.  Back to cited text no. 53
    
54.
Kuns B, Rosani A, Varghese D. Memantine. In: Stat Pearls. Treasure Island, FL, USA: StatPearls Publishing LLC; 2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK500025/. [Last accessed on 2020 Oct 18].  Back to cited text no. 54
    
55.
Tocco M, Bayles K, Lopez OL, Hofbauer RK, Pejović V, Miller ML, et al. Effects of memantine treatment on language abilities and functional communication: A review of data. Aphasiology 2013;28:236-57.  Back to cited text no. 55
    
56.
Berthier ML, Green C, Lara JP, Higueras C, Barbancho MA, Dávila G, et al. Memantine and constraint-induced aphasia therapy in chronic poststroke aphasia. Ann Neurol 2009;65:577-85.  Back to cited text no. 56
    
57.
Barbancho MA, Berthier ML, Navas-Sánchez P, Dávila G, Green-Heredia C, García-Alberca JM, et al. Bilateral brain reorganization with memantine and constraint-induced aphasia therapy in chronic post-stroke aphasia: An ERP study. Brain Lang 2015;145-146:1-10.  Back to cited text no. 57
    
58.
Chollet F, Rigal J, Marque P, Barbieux-Guillot M, Raposo N, Fabry V, et al. Serotonin selective reuptake inhibitors (SSRIs) and stroke. Curr Neurol Neurosci Rep 2018;18:100.  Back to cited text no. 58
    
59.
Rocka A, Madras D, Piędel F, Jasielski P, Szumna K. Does SSRI have a neuroprotective effect in patent after ischemic stroke? J Educ Health Sport 2020;10:32-9.  Back to cited text no. 59
    
60.
Siepmann T, Penzlin AI, Kepplinger J, Illigens BM, Weidner K, Reichmann H, et al. Selective serotonin reuptake inhibitors to improve outcome in acute ischemic stroke: Possible mechanisms and clinical evidence. Brain Behav 2015;5:e00373.  Back to cited text no. 60
    
61.
McCann SK, Irvine C, Mead GE, Sena ES, Currie GL, Egan KE, et al. Efficacy of antidepressants in animal models of ischemic stroke: A systematic review and meta-analysis. Stroke 2014;45:3055-63.  Back to cited text no. 61
    
62.
Dam M, Tonin P, De Boni A, Pizzolato G, Casson S, Ermani M, et al. Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. Stroke 1996;27:1211-4.  Back to cited text no. 62
    
63.
Chollet F, Tardy J, Albucher JF, Thalamas C, Berard E, Lamy C, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): A randomised placebo-controlled trial. Lancet Neurol 2011;10:123-30.  Back to cited text no. 63
    
64.
Mead GE, Hsieh CF, Hackett M. Selective serotonin reuptake inhibitors for stroke recovery. JAMA 2013;310:1066-7.  Back to cited text no. 64
    
65.
Zhou S, Liu S, Liu X, Zhuang W. Selective serotonin reuptake inhibitors for functional independence and depression prevention in early stage of post-stroke: A meta-analysis. Medicine (Baltimore) 2020;99:e19062.  Back to cited text no. 65
    
66.
Legg LA, Tilney R, Hsieh CF, Wu S, Lundström E, Rudberg AS, et al. Selective serotonin reuptake inhibitors for stroke recovery. Stroke 2020;51:e142-3.  Back to cited text no. 66
    
67.
Tanaka Y, Albert M. Serotonergic therapy shows promise for aphasia. In: Neurology Today.Wolters Kluwer Business Offices in New York, NY, USA: AAN Publications; 2004. Available form: https://journals.lww.com/neurotodayonline/Fulltext/2004/06000/SEROTONERGIC_THERAPY_SHOWS_PROMISE_FOR_APHASIA.17.aspx. [Last accessed on 2020 Oct 22].  Back to cited text no. 67
    
68.
Hillis AE, Beh YY, Sebastian R, Breining B, Tippett DC, Wright A, et al. Predicting recovery in acute poststroke aphasia. Ann Neurol 2018;83:612-22.  Back to cited text no. 68
    
69.
Yeo SH, Kong KH, Lim DC, Yau WP. Use of selective serotonin reuptake inhibitors and outcomes in stroke rehabilitation: A prospective observational pilot cohort study. Drugs R D 2019;19:367-79.  Back to cited text no. 69
    
70.
Adderall CII. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/011522s042lbl.pdf. [Last accessed on 2020 Oct 19].  Back to cited text no. 70
    
71.
Walker-Batson D, Mehta J, Smith P, Johnson M. Amphetamine and other pharmacological agents in human and animal studies of recovery from stroke. Prog Neuropsychopharmacol Biol Psychiatry 2016;64:225-30.  Back to cited text no. 71
    
72.
Walker-Batson D, Devous MD, Curtis SS, Unwin H, Greenlee RG. Response to amphetamine to facilitate recovery from aphasia subsequent to stroke. Clin Aphasiol 1990;20:137-43.  Back to cited text no. 72
    
73.
Walker-Batson D, Curtis S, Natarajan R, Ford J, Dronkers N, Salmeron E, et al. A double-blind, placebo-controlled study of the use of amphetamine in the treatment of aphasia. Stroke 2001;32:2093-8.  Back to cited text no. 73
    
74.
Spiegel DR, Alexander G. A case of nonfluent aphasia treated successfully with speech therapy and adjunctive mixed amphetamine salts. J Neuropsychiatry Clin Neurosci 2011;23:E24.  Back to cited text no. 74
    
75.
Keser Z, Dehgan MW, Shadravan S, Yozbatiran N, Maher LM, Francisco GE. Combined dextroamphetamine and transcranial direct current stimulation in poststroke aphasia. Am J Phys Med Rehabil 2017;96:S141-5.  Back to cited text no. 75
    
76.
Stroemer RP, Kent TA, Hulsebosch CE. Enhanced neocortical neural sprouting, synaptogenesis, and behavioral recovery with D-amphetamine therapy after neocortical infarction in rats. Stroke 1998;29:2381-93.  Back to cited text no. 76
    
77.
Porch B, Feeney D. Effects of antihypertensive drugs on recovery from aphasia. Clin Aphasiol 1986;16:309-14.  Back to cited text no. 77
    
78.
McNeil MR, Doyle PJ, Spencer KA, Goda AJ, Flores D, Small SL. A double-blind, placebo-controlled study of pharmacological and behavioural treatment of lexical-semantic deficits in aphasia. Aphasiology 1997;11:385-400.  Back to cited text no. 78
    
79.
Whiting E, Chenery HJ, Chalk J, Copland DA. Dexamphetamine boosts naming treatment effects in chronic aphasia. J Int Neuropsychol Soc 2007;13:972-9.  Back to cited text no. 79
    
80.
Yamada N, Kakuda W, Yamamoto K, Momosaki R, Abo M. Atomoxetine administration combined with intensive speech therapy for post-stroke aphasia: Evaluation by a novel SPECT method. Int J Neurosci 2016;126:829-38.  Back to cited text no. 80
    
81.
Beversdorf DQ, Sharma UK, Phillips NN, Notestine MA, Slivka AP, Friedman NM, et al. Effect of propranolol on naming in chronic Broca's aphasia with anomia. Neurocase 2007;13:256-9.  Back to cited text no. 81
    
82.
Walker-Batson D, Unwin H, Curtis S, Allen E, Wood M, Smith P, et al. Use of amphetamine in the treatment of aphasia. Restor Neurol Neurosci 1992;4:47-50.  Back to cited text no. 82
    
83.
Strattera (Atomoxetine HCl). Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021411s004s012s013s015s021lbl.pdf. [Last accessed on 2020 Sep 23].  Back to cited text no. 83
    
84.
Basile LM. Atomoxetine. In: Kristin F, editor. The Gale Encyclopedia of Prescription Drugs: A Comprehensive Guide to the Most Common Medications. Vol. 1. Farmington Hills, MI, USA: Gale eBooks; 2015. Available from: https://link.gale.com/apps/doc/CX3626600033/GVRL?u=txshracd2509&sid=GVRL&xid=fa12c922. [Last accessed on 2020 Oct 19].  Back to cited text no. 84
    
85.
Inderal® (Propranolol Hydrochloride) Tablets. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/016418s080,016762s017,017683s008lbl.pdf. [Last accessed on 2020 Oct 18].  Back to cited text no. 85
    
86.
Marangolo P, Fiori V, Shofany J, Gili T, Caltagirone C, Cucuzza G, et al. Moving beyond the brain: Transcutaneous spinal direct current stimulation in post-stroke aphasia. Front Neurol 2017;8:400.  Back to cited text no. 86
    
87.
Lefaucheur JP, Antal A, Ayache SS, Benninger DH, Brunelin J, Cogiamanian F, et al. Evidence-based guidelines on the therapeutic use of transcranial direct current stimulation (tDCS). Clin Neurophysiol 2017;128:56-92.  Back to cited text no. 87
    
88.
Marangolo P, Fiori V, Calpagnano MA, Campana S, Razzano C, Caltagirone C, et al. tDCS over the left inferior frontal cortex improves speech production in aphasia. Front Hum Neurosci 2013;7:539.  Back to cited text no. 88
    
89.
Biou E, Cassoudesalle H, Cogné M, Sibon I, De Gabory I, Dehail P, et al. Transcranial direct current stimulation in post-stroke aphasia rehabilitation: A systematic review. Ann Phys Rehabil Med 2019;62:104-21.  Back to cited text no. 89
    
90.
Otal B, Olma MC, Flöel A, Wellwood I. Inhibitory non-invasive brain stimulation to homologous language regions as an adjunct to speech and language therapy in post-stroke aphasia: A meta-analysis. Front Hum Neurosci 2015;9:236.  Back to cited text no. 90
    
91.
Shah-Basak PP, Wurzman R, Purcell JB, Gervits F, Hamilton R. Fields or flows? A comparative metaanalysis of transcranial magnetic and direct current stimulation to treat post-stroke aphasia. Restor Neurol Neurosci 2016;34:537-58.  Back to cited text no. 91
    
92.
Elsner B, Kugler J, Pohl M, Mehrholz J. Transcranial direct current stimulation (tDCS) for improving aphasia in patients after stroke. Cochrane Dataase Syst Rev 2019;5:1465-1858. DOI 10.1002/14651858.CD008760.  Back to cited text no. 92
    
93.
Rosso C, Arbizu C, Dhennain C, Lamy JC, Samson Y. Repetitive sessions of tDCS to improve naming in post-stroke aphasia: Insights from an individual patient data (IPD) meta-analysis. Restor Neurol Neurosci 2018;36:107-16.  Back to cited text no. 93
    
94.
Woodhead ZV, Kerry SJ, Aguilar OM, Ong YH, Hogan JS, Pappa K, et al. Randomized trial of iReadMore word reading training and brain stimulation in central alexia. Brain 2018;141:2127-41.  Back to cited text no. 94
    
95.
Wu D, Wang J, Yuan Y. Effects of transcranial direct current stimulation on naming and cortical excitability in stroke patients with aphasia. Neurosci Lett 2015;589:115-20.  Back to cited text no. 95
    
96.
You DS, Kim DY, Chun MH, Jung SE, Park SJ. Cathodal transcranial direct current stimulation of the right Wernicke's area improves comprehension in subacute stroke patients. Brain Lang 2011;119:1-5.  Back to cited text no. 96
    
97.
Di Pino G, Pellegrino G, Assenza G, Capone F, Ferreri F, Formica D, et al. Modulation of brain plasticity in stroke: A novel model for neurorehabilitation. Nat Rev Neurol 2014;10:597-608.  Back to cited text no. 97
    
98.
Saur D, Lange R, Baumgaertner A, Schraknepper V, Willmes K, Rijntjes M, et al. Dynamics of language reorganization after stroke. Brain 2006;129:1371-84.  Back to cited text no. 98
    
99.
Pestalozzi MI, Di Pietro M, Martins Gaytanidis C, Spierer L, Schnider A, Chouiter L, et al. Effects of prefrontal transcranial direct current stimulation on lexical access in chronic poststroke aphasia. Neurorehabil Neural Repair 2018;32:913-23.  Back to cited text no. 99
    
100.
Meinzer M, Darkow R, Lindenberg R, Flöel A. Electrical stimulation of the motor cortex enhances treatment outcome in post-stroke aphasia. Brain 2016;139:1152-63.  Back to cited text no. 100
    
101.
Sebastian R, Saxena S, Tsapkini K, Faria AV, Long C, Wright A, et al. Cerebellar tDCS: A novel approach to augment language treatment post-stroke. Front Hum Neurosci 2016;10:695.  Back to cited text no. 101
    
102.
Marangolo P, Fiori V, Caltagirone C, Pisano F, Priori A. Transcranial cerebellar direct current stimulation enhances verb generation but not verb naming in poststroke aphasia. J Cogn Neurosci 2018;30:188-99.  Back to cited text no. 102
    
103.
Turkeltaub PE, Swears MK, D'Mello AM, Stoodley CJ. Cerebellar tDCS as a novel treatment for aphasia? Evidence from behavioral and resting-state functional connectivity data in healthy adults. Restor Neurol Neurosci 2016;34:491-505.  Back to cited text no. 103
    
104.
Ackermann H, Mathiak K, Riecker A. The contribution of the cerebellum to speech production and speech perception: Clinical and functional imaging data. Cerebellum 2007;6:202-13.  Back to cited text no. 104
    
105.
Fridriksson J, Elm J, Stark BC, Basilakos A, Rorden C, Sen S, et al. BDNF genotype and tDCS interaction in aphasia treatment. Brain Stimul 2018;11:1276-81.  Back to cited text no. 105
    
106.
Vila-Nova C, Lucena PH, Lucena R, Armani-Franceschi G, Campbell FQ. Effect of anodal tDCS on articulatory accuracy, word production, and syllable repetition in subjects with aphasia: A crossover, double-blinded, sham-controlled trial. Neurol Ther 2019;8:411-24.  Back to cited text no. 106
    
107.
Lefaucheur JP, Aleman A, Baeken C, Benninger DH, Brunelin J, Di Lazzaro V, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018). Clin Neurophysiol 2020;131:474-528.  Back to cited text no. 107
    
108.
Vuksanović J, Jelić MB, Milanović SD, Kačar K, Konstantinović L, Filipović SR. Improvement of language functions in a chronic non-fluent post-stroke aphasic patient following bilateral sequential theta burst magnetic stimulation. Neurocase 2015;21:244-50.  Back to cited text no. 108
    
109.
Yoon TH, Han SJ, Yoon TS, Kim JS, Yi TI. Therapeutic effect of repetitive magnetic stimulation combined with speech and language therapy in post-stroke non-fluent aphasia. NeuroRehabilitation 2015;36:107-14.  Back to cited text no. 109
    
110.
Hu XY, Zhang T, Rajah GB, Stone C, Liu LX, He JJ, et al. Effects of different frequencies of repetitive transcranial magnetic stimulation in stroke patients with non-fluent aphasia: A randomized, sham-controlled study. Neurol Res 2018;40:459-65.  Back to cited text no. 110
    
111.
Thiel A, Hartmann A, Rubi-Fessen I, Anglade C, Kracht L, Weiduschat N, et al. Effects of noninvasive brain stimulation on language networks and recovery in early poststroke aphasia. Stroke 2013;44:2240-6.  Back to cited text no. 111
    
112.
Bae EH, Schrader LM, Machii K, Alonso-Alonso M, Riviello JJ Jr., Pascual-Leone A, et al. Safety and tolerability of repetitive transcranial magnetic stimulation in patients with epilepsy: A review of the literature. Epilepsy Behav 2007;10:521-8.  Back to cited text no. 112
    
113.
Bikson M, Grossman P, Thomas C, Zannou AL, Jiang J, Adnan T, et al. Safety of transcranial direct current stimulation: Evidence based update 2016. Brain Stimul 2016;9:641-61.  Back to cited text no. 113
    



 
 
    Tables

  [Table 1], [Table 2], [Table 3], [Table 4], [Table 5], [Table 6], [Table 7]



 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
Abstract
Introduction
Methods
Pharmacologic Tr...
Noninvasive Brai...
Discussion
Conclusion
References
Article Tables

 Article Access Statistics
    Viewed1494    
    Printed46    
    Emailed0    
    PDF Downloaded152    
    Comments [Add]    

Recommend this journal


[TAG2]
[TAG3]
[TAG4]